| Literature DB >> 29903005 |
Maryam Meskini1, Davoud Esmaeili2.
Abstract
BACKGROUND: The outbreak of MDR and XDR strains of Pseudomonas aeruginosa and increased resistance to infection in burn patients recommend the issue of infection control. In this research, we study ZOUSH herbal ointment for gene silencing of Pseudomonas aeruginosa.Entities:
Keywords: Burns; Honey; Mentha Mozaffariani Jamzad; Polyurethane; Pseudomonas aeruginosa; Real-time RT-PCR; Satureja khuzestaniea; ZOUSH; Zataria multiflora
Mesh:
Substances:
Year: 2018 PMID: 29903005 PMCID: PMC6003004 DOI: 10.1186/s12906-018-2251-4
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Grouping of mice in this study
| Groups | Burn Wounds | Exposure to bacteria | No. mice | Ointment |
|---|---|---|---|---|
| Group 1 (negative control) | ✓ | ✓ | 20 | No Ointment |
| Group 2 | ✓ | ✓ | 20 | Base Ointment (without active ingredient) |
| Group 3 | ✓ | ✓ | 20 | ZOUSH Ointment |
| Group 4 (positive control) | ✓ | ✓ | 20 | Akbar 1 Ointment (herbal ointment) |
| Group 5 (positive control) | ✓ | ✓ | 20 | Silver sulfadiazine Ointment |
MIC Results for ZOUSH Ointment compounds: active ingredients as single, dual, triple
| Substances | MIC |
|---|---|
|
| 0.079 |
|
| 0.079 |
|
| 0.158 |
| Honey | 0.079 |
| 0.059 | |
| 0.079 | |
| 0.079 | |
| 0.039 |
Mean count of Pseudomonas aeruginosa isolated in each study phase. (CFU/g)
| Groups | Study 1 | Study 2 | Study 3 | Study4 |
|---|---|---|---|---|
| Base Ointment (without active ingredient) | 906 | 2778 | 2222 | 1667 |
| No Ointment | 725 | 2223 | 1945 | 1111 |
| Akbar 1 Ointment (herbal ointment) | 817 | 277 | 139 | 95 |
| Silver sulfadiazine Ointment | 214 | 1850 | 184 | 18 |
| ZOUSH Ointment | 123 | 97 | 70 | 0 |
Fig. 1exoS gene amplification curve using Real-time RT-PCR technique: As outlined in the figure, the Ct level of the exoS gene was different before and after treatment (Ct before treatment = 14.32 and Ct after treatment = 12.42). However, there was no change in the Ct level of the fabD gene before and after treatment (Ct before treatment = 14.56 and Ct after treatment = 14.06). Therefore, the amount of the exoS gene expression changed after treatment, while the FabD gene expression had no change before and after treatment
Fig. 2lasA gene amplification curve using Real-time RT-PCR technique: As outlined in the figure, the Ct level of the lasA gene was different before and after treatment (Ct before treatment = 12.64 and Ct after treatment = 10.38). However, there was no change in the Ct level of the gyrA gene before and after treatment (Ct before treatment = 14.56 and Ct after treatment = 14.06). Therefore, the amount of the lasA gene expression changed after treatment, while the gyrA gene expression had no change before and after treatment
Fig. 3lasB gene amplification curve using Real-time RT-PCR technique: As outlined in the figure, the Ct level of the lasB gene was different before and after treatment (Ct before treatment = 13.24 and Ct after treatment = 12.64). However, there was no change in the Ct level of the gyrA gene before and after treatment (Ct before treatment = 14.56 and Ct after treatment = 14.06). Therefore, the amount of the lasB gene expression changed after treatment, while the gyrA gene expression had no change before and after treatment